REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
20/07/2026
Voltar para busca
Dado oficial do USPTO
GK
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
20/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 45
Data de depósito
11/09/2019
Data de registro
20/07/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/07/2021
Última transação
20/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
JP
Examinador
CHANG, ELIZABETH YI HSUAN
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the stylized Greek letter "Delta" and the stylized Latin letters "GK".
Titulares e representantes
Titulares
CHUGAI SEIYAKU KABUSHIKI KAISHA (Chugai Pharmaceutical Co., Ltd.)
Representantes
BASSAM N. IBRAHIM BUCHANAN INGERSOLL & ROONEY PC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for human use to minimize heterogeneity caused by endogenous enzymes in the course of cell culture for preventing or treating infectious and parasitic diseasescancerblood and blood-forming organs diseases and disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systempregnancychildbirth and the puerperiumcertain conditions originating in the perinatal periodcongenital malformationsdeformations and chromosomal abnormalitiespharmaceutical antibodies or its fragments or its derivatives; cells and genes that produce antibodiesfragments of antibodies or derivatives of antibodies for medical use
Classe 42
Pharmaceutical research and development services and providing information about medical and scientific research in the field of pharmaceuticals
Classe 45
Granting of licenses to others for the use of industrial property rights and copyright
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/01/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/01/2022
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
01/12/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
01/12/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
20/10/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
20/07/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/05/2021
PUBO
PUBLISHED FOR OPPOSITION
04/05/2021
GPNX
NOTIFICATION PROCESSED BY IB
02/05/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/04/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
21/04/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/04/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
14/04/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/04/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/03/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
29/03/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
29/03/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
29/03/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
29/03/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
10/02/2021
EXPI
EX PARTE APPEAL-INSTITUTED
10/02/2021
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
10/02/2021
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
10/02/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/08/2020
GNFR
FINAL REFUSAL E-MAILED
12/08/2020
CNFR
FINAL REFUSAL WRITTEN
12/08/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/07/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
19/06/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
19/06/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
19/06/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
19/06/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
19/06/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
19/06/2020
RFNT
REFUSAL PROCESSED BY IB
15/02/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
24/01/2020
RFRR
REFUSAL PROCESSED BY MPU
24/01/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/12/2019
CNRT
NON-FINAL ACTION WRITTEN
12/12/2019
DOCK
ASSIGNED TO EXAMINER
11/12/2019
MAFR
APPLICATION FILING RECEIPT MAILED
29/11/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/11/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/11/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace GK ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.